News | Population Health | January 10, 2019

Mobile App Data Collection Shows Promise for Population Health Surveys

Researchers evaluate Medable Inc.’s mobile health survey solution as potential way to eliminate barriers to large-scale data collection

Mobile App Data Collection Shows Promise for Population Health Surveys

January 10, 2019 — Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study timeframes and create more comprehensive sample sizes, according to research published in Survey Practice.

“It is critical that health and other national surveys represent the voice and experience of all Americans,” said senior author Ingrid Oakley-Girvan, senior vice president of research and strategy at Medable Inc., research director at the Public Health Institute, and associate member of the Canary Center at Stanford for Cancer Early Detection and the Stanford Cancer Institute. “Smartphone survey data can help policy makers allocate resources in realtime to respond to disease outbreaks such as opioid addiction. Our work sheds light on the value of smartphones to address declining participation rates, rising survey costs and poor coverage across demographics.”

Oakley-Girvan and co-authors Yasamin Miller, Cyrus DiCiccio, Juan Lavista, Cheryl Gore-Felton, Amanda Richardson, Carlos Acle, Jeff Hancock, Lorene Nelson and Oxana Palesh were interested in the impact that smartphones can have on health data survey collection.

They studied the response to a mobile app survey, built on the Medable Inc. platform, by deploying it in a college student population to determine if students would download the app, and to determine if the app would retain individuals in a study, two significant barriers being faced by researchers conducting population health surveys.  

“Our findings show that mobile app data collection can fundamentally change survey research,” said Miller, first author and founder and managing director of YMG. “Using mobile apps could create a shift in health surveys, which could eventually lead to faster and more accurate health policies and cures.”

Declining response rates to traditional telephone surveys are hindering researchers in their abilities to recruit and study the most pressing medical issues. The study used Medable Inc.’s platform to provide efficient real-world data collection, monitoring and analysis.

The researchers partnered with faculty from Stanford University, the Cancer Prevention Institute of California (CPIC), OneTree, YMG and Castleton University, to leverage Medable’s platform to collect behavioral health and substance use data. The researchers built and deployed two apps in under six weeks.

Medable’s end-to-end (E2E) platform enables researchers without developer expertise to create and deploy HIPAA-compliant iOS and Android apps for clinical trials or research studies. “Creating mobile applications on a short timeline would not have been possible without the use of Medable’s Axon,” said Miller. “Medable’s platform enabled team members without coding expertise to contribute and play key roles in developing the study.”

For more information: www.medable.com

Reference

Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now